{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T12:25:06Z","timestamp":1787228706579,"version":"build-2736575974"},"reference-count":67,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The therapeutic landscape of multiple myeloma (MM) has undergone a profound transformation, with highly effective combination regimens and immune-based therapies enabling unprecedented rates of deep and durable responses. As a result, conventional baseline risk stratification alone is increasingly insufficient to explain the heterogeneity of clinical outcomes or to guide treatment throughout the disease course. This evolving paradigm has shifted attention toward dynamic, response-adapted disease monitoring centered on measurable residual disease (MRD) and the biological interaction between residual tumor cells and the host immune system. Bone marrow-based next-generation flow cytometry and next-generation sequencing currently represent the most extensively validated approaches for MRD assessment, while functional imaging, mass spectrometry, circulating tumor DNA, and other minimally invasive technologies are expanding the ability to monitor spatially heterogeneous disease and longitudinal clonal evolution. Although sustained MRD negativity has emerged as one of the most powerful prognostic biomarkers in MM, its clinical significance is influenced by multiple factors, including timing of assessment, sensitivity, durability of response, baseline disease biology, imaging findings, and the quality of immune reconstitution. Increasing evidence indicates that relapse following MRD negativity reflects not only residual tumor burden below the limits of detection but also a dynamic biological process driven by clonal evolution, microenvironmental protection, immune escape, and therapeutic selection pressure. Immune profiling provides complementary information by characterizing immune competence, including T-cell and natural killer-cell function, immune reconstitution after therapy, regulatory and myeloid immunosuppressive networks, and the immune fitness required for effective T-cell redirection and the capacity to sustain effective antitumor immune surveillance. Integrating longitudinal MRD kinetics with immune biomarkers has the potential to improve risk discrimination, identify biologically discordant disease states, and support rational strategies for treatment intensification, de-escalation, or discontinuation within prospective clinical trials. In the era of anti-CD38 antibodies, CAR T-cell therapy, bispecific antibodies, and emerging multi-antigen immunotherapies, disease monitoring is evolving beyond the assessment of tumor burden alone. Future of MM management will likely rely on multidimensional monitoring frameworks that integrate MRD, immune competence, spatial disease assessment, circulating biomarkers, and computational risk modeling to enable truly personalized, biology-driven patient care.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1934257","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T11:43:17Z","timestamp":1787226197000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["From static risk to dynamic disease monitoring: the role of MRD and immune profiling in multiple myeloma"],"prefix":"10.3389","volume":"17","author":[{"given":"Maria Eugenia","family":"Alvaro","sequence":"first","affiliation":[{"name":"Hematology Unit, Department of Onco-Hematology, Azienda Ospedaliera (AO) of Cosenza","place":["Cosenza, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrica Antonia","family":"Martino","sequence":"additional","affiliation":[{"name":"Hematology Unit, Department of Onco-Hematology, Azienda Ospedaliera (AO) of Cosenza","place":["Cosenza, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santino","family":"Caserta","sequence":"additional","affiliation":[{"name":"Hematology Unit, Department of Onco-Hematology, Azienda Ospedaliera (AO) of Cosenza","place":["Cosenza, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Bruzzese","sequence":"additional","affiliation":[{"name":"Hematology Unit, Department of Onco-Hematology, Azienda Ospedaliera (AO) of Cosenza","place":["Cosenza, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Amodio","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University of Catanzaro","place":["Catanzaro, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Lucia","sequence":"additional","affiliation":[{"name":"Hematology Unit, Department of Onco-Hematology, Azienda Ospedaliera (AO) of Cosenza","place":["Cosenza, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Olivito","sequence":"additional","affiliation":[{"name":"Hematology Unit, Department of Onco-Hematology, Azienda Ospedaliera (AO) of Cosenza","place":["Cosenza, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Labanca","sequence":"additional","affiliation":[{"name":"Hematology Unit, Department of Onco-Hematology, Azienda Ospedaliera (AO) of Cosenza","place":["Cosenza, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Mendicino","sequence":"additional","affiliation":[{"name":"Hematology Unit, Department of Onco-Hematology, Azienda Ospedaliera (AO) of Cosenza","place":["Cosenza, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fortunato","family":"Morabito","sequence":"additional","affiliation":[{"name":"Associazione Italiana contro le Leucemie - Linfomi e Mieloma (AIL) Sezione di Cosenza","place":["Cosenza, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Vigna","sequence":"additional","affiliation":[{"name":"Hematology Unit, Department of Onco-Hematology, Azienda Ospedaliera (AO) of Cosenza","place":["Cosenza, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Gentile","sequence":"additional","affiliation":[{"name":"Hematology Unit, Department of Onco-Hematology, Azienda Ospedaliera (AO) of Cosenza","place":["Cosenza, Italy"]},{"name":"Department of Pharmacy, Health and Nutritional Science, University of Calabria","place":["Rende, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: A report from international myeloma working group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02614","article-title":"Second revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: A European Myeloma Network (EMN) report within the HARMONY Project","volume":"40","author":"D'Agostino","year":"2022","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/ph19020320","article-title":"Next-generation biomarkers in multiple myeloma: Advancing diagnosis, risk stratification, and precision therapy beyond current guidelines","volume":"19","author":"Lopes","year":"2026","journal-title":"Pharmaceuticals"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2025.2610373","article-title":"Reshaping multiple myeloma treatment: Recent breakthroughs","volume":"26","author":"Martino","year":"2025","journal-title":"Expert Opin Pharmacother"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-cancerbio-061421-014236","article-title":"Next-generation therapies for multiple myeloma","volume":"8","author":"Meermeier","year":"2024","journal-title":"Annu Rev Cancer Biol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.284662","article-title":"Role of minimal residual disease assessment in multiple myeloma","volume":"109","author":"Szalat","year":"2024","journal-title":"Haematologica"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.70203","article-title":"Minimal residual disease as a biological trait: Rethinking disease persistence in hematologic Malignancies","volume":"117","author":"Caserta","year":"2026","journal-title":"Eur J Haematol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1177\/20406207241245194","article-title":"Treatment of multiple myeloma: What is the impact on T-cell function","volume":"15","author":"Li","year":"2024","journal-title":"Ther Adv Hematol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.21037\/actr-25-66","article-title":"The role of minimal residual disease measurement in multiple myeloma","volume":"4","author":"Mohan Lal","year":"2025","journal-title":"AME Clin Trials Rev"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol33050249","article-title":"High-risk cytogenetic multiple myeloma remains a therapeutic challenge: A 15-year real-world analysis","volume":"33","author":"Awadallah","year":"2026","journal-title":"Curr Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2026.s2.14070","article-title":"P65 | Functional high risk multiple myeloma in the anti-CD38 quadruplet era: Redefinition through real world data","volume":"111","author":"Mor\u00e8","year":"2026","journal-title":"Haematologica"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1740112","article-title":"MRD in multiple myeloma: The clinical perspective","volume":"15","author":"Caravita di Toritto","year":"2026","journal-title":"Front Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"5335","DOI":"10.1038\/s41467-023-40966-8","article-title":"Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma","volume":"14","author":"Coffey","year":"2023","journal-title":"Nat Commun"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15143687","article-title":"Minimal residual disease in multiple myeloma: Past, present, and future","volume":"15","author":"Medina-Herrera","year":"2023","journal-title":"Cancers"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000001197","article-title":"Advancing MRD detection in multiple myeloma: Technologies, applications, and future perspectives","volume":"48","author":"Chen","year":"2025","journal-title":"Am J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.29","article-title":"Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"Flores-Montero","year":"2017","journal-title":"Leukemia"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/diseases13100320","article-title":"Applications of multiparameter flow cytometry in the diagnosis, prognosis, and monitoring of multiple myeloma patients","volume":"13","author":"Leonardos","year":"2025","journal-title":"Dis (Basel Switzerland)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(17)30189-4","article-title":"Role of 18F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: A consensus statement by the International Myeloma Working Group","volume":"18","author":"Cavo","year":"2017","journal-title":"Lancet Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.72023","article-title":"Prognostic value of next-generation flow cytometry versus dual-tracer PET\/CT for minimal residual disease assessment in multiple myeloma","volume":"15","author":"Zhang","year":"2026","journal-title":"Cancer Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024015685","article-title":"Clinical applications of mass spectrometry in multiple myeloma","volume":"9","author":"Derman","year":"2025","journal-title":"Blood Adv"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-2767","article-title":"Monitoring minimal residual disease in patients with multiple myeloma by targeted tracking serum M-protein using mass spectrometry (EasyM)","volume":"30","author":"Fan","year":"2024","journal-title":"Clin Cancer Research: Off J Am Assoc For Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70405","article-title":"Minimally invasive characterization of peripheral blood measurable residual disease in multiple myeloma using high-sensitivity detection of ctDNA by next-generation sequencing","volume":"10","author":"Buenache","year":"2026","journal-title":"HemaSphere"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2025.2596804","article-title":"MRD contamination in peripheral blood autologous stem cell grafts: Implications for relapse and prognosis in multiple myeloma","volume":"67","author":"Lin","year":"2026","journal-title":"Leukemia Lymphoma"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-026-01199-z","article-title":"Evidence for the monitoring of minimal residual disease dynamics to guide clinical practice in patients with multiple myeloma","volume":"21","author":"Gan","year":"2026","journal-title":"Targeted Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.70193","article-title":"Relapse despite MRD negativity in multiple myeloma: Toward integrated risk prediction","volume":"117","author":"Martino","year":"2026","journal-title":"Eur J Haematol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/cancers18121873","article-title":"The shape-shifting myeloma: Adaptive plasticity as a hallmark of relapse and refractoriness","volume":"18","author":"Nasso","year":"2026","journal-title":"Cancers"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-0523","article-title":"The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, and apoptosis-resistant phenotype","volume":"11","author":"Yaccoby","year":"2005","journal-title":"Clin Cancer Research: Off J Am Assoc For Cancer Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1346211","article-title":"Different evasion strategies in multiple myeloma","volume":"15","author":"Wang","year":"2024","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11092513","article-title":"The leading role of the immune microenvironment in multiple myeloma: A new target with a great prognostic and clinical value","volume":"11","author":"Desantis","year":"2022","journal-title":"J Clin Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1613265","article-title":"Deciphering the bone marrow microenvironment\u2019s role in multiple myeloma immunotherapy resistance","volume":"16","author":"Iannozzi","year":"2025","journal-title":"Front Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040625","article-title":"The immune microenvironment in multiple myeloma: Friend or foe","volume":"13","author":"Lopes","year":"2021","journal-title":"Cancers"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13020217","article-title":"The role of tumor microenvironment in multiple myeloma development and progression","volume":"13","author":"Garc\u00eda-Ortiz","year":"2021","journal-title":"Cancers"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113245","article-title":"Deep phenotyping reveals distinct immune signatures correlating with prognostication, treatment responses, and MRD status in multiple myeloma","volume":"12","author":"Papadimitriou","year":"2020","journal-title":"Cancers"},{"key":"B37","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s43018-020-0053-3","article-title":"Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma","volume":"1","author":"Zavidij","year":"2020","journal-title":"Nat Cancer"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.03.007","article-title":"Lymphocyte subset recovery and outcome after autologous hematopoietic stem cell transplantation for plasma cell myeloma","volume":"20","author":"Rueff","year":"2014","journal-title":"Biol Blood Marrow Transplantation: J Am Soc For Blood Marrow Transplant"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.trim.2022.101544","article-title":"Prognostic impact of natural killer cell recovery on minimal residual disease after autologous stem cell transplantation in multiple myeloma","volume":"71","author":"Keruakous","year":"2022","journal-title":"Transplant Immunol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1158\/2326-6066.CIR-15-0055","article-title":"T-cell exhaustion in multiple myeloma relapse after autotransplant: Optimal timing of immunotherapy","volume":"4","author":"Chung","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.663748","article-title":"Predictive role of immune profiling for survival of multiple myeloma patients","volume":"12","author":"Zhaoyun","year":"2021","journal-title":"Front Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00217-X","article-title":"Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): Final analysis of an open-label, randomised, phase 2 trial","volume":"10","author":"Voorhees","year":"2023","journal-title":"Lancet Haematology"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet (London England)"},{"key":"B47","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/ejh.70167","article-title":"Elranatamab in relapsed\/refractory multiple myeloma: Mechanisms, clinical evidence, and emerging perspectives","volume":"117","author":"Alvaro","year":"2026","journal-title":"Eur J Haematol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16193288","article-title":"Measurable residual disease testing in multiple myeloma following T-cell redirecting therapies","volume":"16","author":"Shim","year":"2024","journal-title":"Cancers"},{"key":"B51","doi-asserted-by":"publisher","first-page":"997","DOI":"10.2147\/ITT.S534784","article-title":"T cells dysfunction in multiple myeloma","volume":"14","author":"Cai","year":"2025","journal-title":"Immunotargets Ther"},{"key":"B52","article-title":"Minimal residual disease and complete response in multiple myeloma: use as endpoints to support accelerated approval","volume-title":"Draft Guidance for Industry","year":"2026"},{"key":"B53","article-title":"Reflection paper on the use of measurable residual disease as a clinical endpoint in multiple myeloma studies","year":"2022"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01935","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma","volume":"40","author":"Costa","year":"2022","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024027686","article-title":"Sustained bone marrow and imaging MRD negativity for 3 years drives discontinuation of maintenance post-ASCT in myeloma","volume":"145","author":"Terpos","year":"2025","journal-title":"Blood"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2505133","article-title":"Measurable residual disease-guided therapy in newly diagnosed myeloma","volume":"393","author":"Perrot","year":"2025","journal-title":"N Engl J Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2026.101177","article-title":"Five trials reshaping multiple myeloma","volume":"7","author":"Talbot","year":"2026","journal-title":"Med (New York NY)"},{"key":"B58","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1186\/s12967-026-07946-0","article-title":"Dynamic biomarker-based machine learning model predicts short-term treatment response in multiple myeloma","volume":"24","author":"Xiong","year":"2026","journal-title":"J Transl Med"},{"key":"B59","doi-asserted-by":"publisher","first-page":"2024.04.01.24305024","DOI":"10.1101\/2024.04.01.24305024","article-title":"Individualized dynamic risk assessment for multiple myeloma","volume":"132","author":"Murie","year":"2024","journal-title":"medRxiv"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-025-02987-6","article-title":"Individualized dynamic risk assessment and treatment selection for multiple myeloma","volume":"132","author":"Murie","year":"2025","journal-title":"Br J Cancer"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16122263","article-title":"The challenging approach to multiple myeloma: From disease diagnosis and monitoring to complications management","volume":"16","author":"Mor\u00e8","year":"2024","journal-title":"Cancers"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2026.s1.34","article-title":"CO21 | Integrated multiomic immune profiling defines the biological basis of minimal residual disease persistence in multiple myeloma","volume":"111","author":"Corsale","year":"2026","journal-title":"Haematologica"},{"key":"B63","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41408-024-01156-x","article-title":"Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP)","volume":"14","author":"Derman","year":"2024","journal-title":"Blood Cancer J"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00236-3","article-title":"Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial","volume":"10","author":"Costa","year":"2023","journal-title":"Lancet Haematology"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-23-0044","article-title":"Time-dependent prognostic value of serological and measurable residual disease assessments after idecabtagene vicleucel","volume":"4","author":"Paiva","year":"2023","journal-title":"Blood Cancer Discov"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-024-01537-2","article-title":"Minimal residual disease-adapted therapy in multiple myeloma: Current evidence and opinions","volume":"26","author":"Meseha","year":"2024","journal-title":"Curr Oncol Rep"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3390\/cancers18081275","article-title":"How laboratory innovations are shaping the future of multiple myeloma care","volume":"18","author":"Caetano","year":"2026","journal-title":"Cancers"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1934257\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T11:43:18Z","timestamp":1787226198000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1934257\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":67,"alternative-id":["10.3389\/fimmu.2026.1934257"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1934257","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"article-number":"1934257"}}